Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Semaglutide, a medication already widely ... highlight a 24% reduction in major kidney disease events among patients with chronic kidney disease (CKD). This breakthrough opens up new possibilities ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

SCIENTISTS BELIEVE SEMAGLUTIDE CAN PREVENT HEART ATTACK ... Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.Video above: Studies ...